BIOCARDIA, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Expense Ratios
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
Revenue Per Share
—
OCF Per Share
—
Return on Equity
-950.1%
Return on Assets
-230.6%
Return on Invested Capital
-755.2%
Current Ratio
1.12
Quick Ratio
1.12
Asset Turnover
0.00
Days Sales Outstanding
0.00
Days Payables Outstanding
—
Days Inventory On Hand
—
Cash Conversion Cycle
—
R&D / Revenue
7563.8%
SBC / Revenue
1277.6%
Capex / Revenue
10.3%
Working Capital
$300K
Net Current Asset Value
$214K
Invested Capital
$895K
OCF / Net Income
0.90
FCF / Net Income
0.90
Accruals Ratio (Sloan)
-23.2%
Net Debt
$-2M
Net Debt / EBITDA
0.30
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-1062.29
Tangible Common Equity
$895K
TCE / Total Assets
26.2%
NOPAT
$-7M
Cash ROIC
-859.5%
WC / Revenue
519.0%
Capex / D&A
0.29
Reinvestment Rate
0.2%
Asset Growth vs Revenue Growth
91.6%
Revenue 5Y CAGR
-39.4%
Book Value 5Y CAGR
-45.8%
Stock Price (FY-end)
$1
Market Cap
—
P/E Ratio
—
P/S Ratio
—
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
—
EV / EBITDA
—
EV / Sales
—
EV / FCF
—
FCF Yield
—
Shareholder Yield
—
R&D Yield
—
Capex Yield
—
Graham Number
—
Shares Variation (YoY)
—
Beta (5Y)
0.86
Cost of Equity
8.8%
52W High
$3
52W Low
$1
Trailing Return 1Y
-49.2%
Trailing Return 5Y
-97.8%
F-Score (Piotroski)
1.00
Z-Score (Altman)
—
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.